Amazon has officially sold half a billion Alexa-enabled devices globally, and it's celebrating the only

Mike Flanagan's The Fall of the House of Usher has so many references to the

Hong Kong’s leader joined state media in blasting Cathay Pacific Airways Ltd. over an incident where flight attendants

The Aspen, Colorado, market for mansions has contracted from the levels seen during the pandemic; year-to-date dollar volume

When we last reviewed Zoho Vault in 2021, we were pleased with the app's basic

Gio Benitez took over the '7th Inning Snacks' series on 'GMA,' visiting Minneapolis to find sumptuous snacks around the Minnesota Twins' home ground

The Czech brewer Budvar, which has been embroiled in a long legal dispute with U.S. beer giant Anheuser-Busch over the use of the Budweiser brand, has registered a fall in its 2022 net profit and exports

Vincent Van Gogh's feverish final months in a French village, when he churned out masterpieces even as he spiralled into despair, are the subject of a one-off...

A high-stakes lawsuit over the future of a widely used abortion drug is likely heading to the US Supreme Court, set to determine the fate of abortion rights access across the country for a second time within two years. Three Republican-appointed judges on a federal appeals court have determined that the federal government did not follow proper procedures when it amended regulations for a commonly used medication abortion drug in 2016. But the restrictions will not immediately take effect. The panel partially upheld a ruling from a Donald Trump-appointed federal judge in Texas, whose sweeping decision earlier this year threatened to strip access to the drug altogether. Nothing in the ruling from a three-judge panel on 16 August will go into effect until the nation’s highest court weighs in. Wednesday’s ruling argues that the US Food and Drug Administration unlawfully expanded access to mifepristone, which was first approved by the federal government more than 20 years ago. Mifepristone was first approved by the FDA in 2000 and is approved for use up to 10 weeks of pregnancy. A vast majority of abortions occur within the first nine weeks of pregnancy. From 2019 through 2020, nearly 93 per cent of all abortions were performed before the 13th week, according to the US Centers for Disease Control and Prevention. The drug – part of a two-drug protocol for medication abortions, the most common form of abortion care in the US – is the subject of a lawsuit from a group of anti-abortion activists represented by right-wing Christian legal group Alliance Defending Freedom, which joined efforts to overturn Roe v Wade at the Supreme Court last year. In April, US District Judge Matthew Kacsmaryk – a former right-wing activist lawyer who was appointed to the federal judiciary by Mr Trump – issued a ruling to suspend the FDA’s approval, which was immediately challenged by abortion rights advocates, providers, major medical groups, drug manufacturers and President Joe Biden’s administration. An initial ruling at the US Court of Appeals for the Fifth Circuit blocked part of that decision but struck down policies for mail-in prescriptions and rules that expanded the drug’s approval for pregnancies up to 10 weeks. On 21 April, the Supreme Court blocked the lower courts’ rulings from taking effect while the case plays out, retaining the status quo while the legal case plays out. Following the Supreme Court’s conservative supermajority decision to revoke a constitutional right to abortion care in Dobbs v Jackson Women’s Health Organization, at least 15 states – mostly across the US South – have effectively banned most abortions and imposed criminal penalties against providers. Abortion rights advocates and providers have warned that eliminating or restricting access to mifepristone could drastically impact an already-fragile landscape for abortion care. A ruling that undermines the FDA’s drug approval process could also open the door for other activist-driven legal battles over other drugs wrapped up in political debates, potentially inviting other destabilising lawsuits to Covid-19 vaccines, contraception, HIV medication, gender-affirming care, and other life-saving drugs. Read More What is mifepristone? The widely used pill in the abortion rights battle at the Supreme Court Abortion rights advocates win major victory in Ohio as voters reject GOP plan to thwart ballot measure Texas women detailed agonising pregnancies after being denied abortions. The state blames doctors Some abortion drug restrictions upheld by in a case bound for Supreme Court Akram criticizes Pakistan Cricket Board for leaving Imran Khan out of Independence Day video Netanyahu voices support for Israel's military after his allies and son lambaste security officials

In Abidjan, the rainy season is coming to an end, but people never put away their "leke" -- cheap, water-resistant, plastic sandals, which have become...

Fall may have only just arrived, but it’s already full-on holiday season at Olive & June. The beloved beauty brand announced both of its highly-anticipated nail polish advent calendars today — and if past years are any indication, we can be sure that they’ll sell out long before the turkey’s even left the oven.

They’ve been talking about it for weeks. In fact since the season-opening Bahrain Grand Prix at the beginning of March, Mercedes have pinpointed this weekend in Imola as a new beginning not only this season, but in this new phase of ground-effect regulations first brought in last year. Toto Wolff has made no secret of F1’s return to traditional European circuits as marking a line in the sand for his team’s prospects in 2023, with Lewis Hamilton and George Russell waiting eagerly in the cockpit to see how far they can reduce the hefty gap – 128 points in the constructors’ standings – to Red Bull out in front. News on Wednesday then of the cancellation of this weekend’s Emilia Romagna Grand Prix comes as a bitter blow to their development plans. In the wider scheme of things, though, Mercedes’ fortunes are very much not a priority. The swiftness of those at Formula 1 on the ground in Imola has not gone unnoticed in the past few days. F1 made the right call to cancel given the severe flooding in the region, even if as expected the race cannot be rescheduled this year. For a sporting entity and a governing body, the FIA, who have repeatedly blundered in recent months, this time the communication between executives, teams and the media was clear throughout in an ever-changing situation. As opposed to Australia in 2020 amid the coronavirus outbreak, as well as Spa in 2021 with heavy rain eventually rendering racing redundant, the call here was decisive while matters of far more importance to local bodies in northern Italy, not least the emergency services, take greater hold. However, given the sheer anticipation at Mercedes for an upgrade package which was set to include a trio of new sidepods, floor and front suspension, this delay is far from ideal. As recently as the weekend, engineering director Andrew Shovlin said: “We took some decisions on how we develop the car – how the car works aerodynamically, how we shape the characteristics of the car, how it is in terms of handling. "What we are going to be bringing to the track in Imola is the first step of that work. This takes quite a long time to develop in the wind tunnel, you can’t just do these things overnight. But the Imola package is the first step in that direction.” At Imola, with three practice sessions, qualifying and a 63-lap race on a traditional European circuit with 19 turns – even if rain was forecast – the technicians and engineers at Mercedes would have gathered swathes of useful data regarding the W14’s performance, consistency and raw speed. An immediate evaluation would have been collated: have the upgrades made the car quicker? But it is no longer the Imola package. Rather unsatisfactorily, it is now the Monaco package. Out of all 23 race circuits on the 2023 schedule, the twisty turns of the principality are perhaps the last place upgrades would want to be tested first time out. The unique dimensions of the Monaco street circuit are out of quilter with the vast majority of tracks on the calendar, meaning upgrades designed to improve the quality of the car over the course of a season may not have a positive impact in Monaco. Thankfully, the race that follows is in Barcelona – a track which before the pandemic was traditionally used for testing. A more appropriate analysis can be ascertained during that weekend in Spain. While Ferrari were also expected to bring improvements this weekend, the focus was undeniably on the Mercedes garage. Now, that anticipation and development plan will have to be re-routed. Hamilton stated after the Azerbaijan Grand Prix in April that he was “counting down the days” until the anticipated upgrades at Imola: the scene of his ultimate humiliation when he was lapped by old foe Max Verstappen in last year’s race. Unfortunately for the seven-time world champion, he will have to wait that little bit longer. Read More F1 Imola Grand Prix cancelled F1 Grand Prix – live: Lewis Hamilton reacts after Imola race cancelled Will Imola Grand Prix be rescheduled? Where are Mercedes and Ferrari? Frankly, you don’t want to hear the answer ‘Nasty piece of work’: Lewis Hamilton’s Mercedes slammed by Toto Wolff Lewis Hamilton would be taking gamble by leaving Mercedes, says former rival